查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1994302

头孢噻呋市场：给药途径、适应症、剂型、最终用户、动物种类 - 全球市场预测 2026-2032

Ceftiofur Market by Route, Indication, Formulation, End User, Animal Type - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，头孢噻呋市场价值将达到 4.7185 亿美元，到 2026 年将成长至 5.0578 亿美元，到 2032 年将达到 8.7282 亿美元，复合年增长率为 9.18%。

主要市场统计数据
基准年 2025 4.7185亿美元
预计年份：2026年 5.0578亿美元
预测年份 2032 872,820,000 美元
复合年增长率 (%) 9.18%

对头孢噻呋在现代兽医学中的治疗作用、监管现状、合理使用预期以及相关人员的优先事项进行全面概述。

头孢噻呋仍然是兽医学中的重要抗生素，因其频谱抗菌作用和在多种畜禽物种中确立的临床效用价值而备受推崇。随着临床证据、兽医标准的不断更新以及全球对合理使用抗生素日益增长的关注，头孢噻呋在治疗通讯协定中的作用也在不断发展。在相关人员权衡治疗效益与监管和公共卫生义务的同时，负责人、农场管理者和供应链规划人员必须清楚了解头孢噻呋的临床适应症、给药途径和製剂选择。

分析了头孢噻呋在兽药领域的应用、供应链、合理使用抗生素和产品创新所发生的变革性变化。

头孢噻呋的研发、分销和处方环境正经历显着变化，其驱动因素包括不断变化的监管环境、供应链重组以及技术创新。日益严格的监管和对合理用药的日益重视正在重塑产品标籤、适应症和配药方式。这些因素促使生产商和经销商重新评估其生命週期策略，增加对处方医生的针对性教育投入，并探索既能支持合理用药又能保持疗效的製剂创新。

对美国于 2025 年实施的关税对头孢噻呋的供应、采购和贸易动态的累积经济和营运影响进行详细评估。

美国2025年加征的关税对头孢噻呋供应链产生了多方面的影响，改变了采购成本结构和下游营运计画。关税调整增加了从受影响的贸易伙伴处采购某些活性成分和製剂的成本，迫使采购团队加快重新评估供应商组合併寻找替代货源。因应措施包括短期战术性调整，例如改变运输路线和调整安全存量基准，以及长期策略决策，例如关键采购的在地化或区域化。

对动物种类、临床适应症、给药途径、製剂选择和最终用户特征如何影响使用模式进行详细的細項分析。

细分市场分析揭示了不同动物种类、临床适应症、给药途径、製剂偏好和终端使用者环境在治疗用途和商业重点方面的差异。依动物种类划分，市场可分为牛、家禽和猪，其中牛又可细分为牛和牛。每个细分市场都展现出独特的疾病特征、给药方案和经济接受度，这些因素都会影响产品选择和给药策略。依疾病适应症划分，胃肠道感染疾病、呼吸道感染疾病和全身性性行为感染的用药情况也存在差异，其中呼吸道感染可细分为牛呼吸道疾病、家禽呼吸道疾病和猪呼吸道疾病。这反映了不同物种的病原体流行情况和防治措施的差异。

区域分析整合了主要全球区域的驱动因素、法规环境、供应链实际情况和临床需求趋势。

区域趋势在头孢噻呋的监管、供应和推广中发挥着至关重要的作用，美洲、欧洲、中东和非洲以及亚太地区呈现出不同的模式。在美洲，各国之间存在着显着的差异，同时各国也努力实现监管协调，这影响着许可期限和处方标准。该地区庞大的商业畜牧业优先考虑生产力和疾病预防，因此对兼顾疗效、合规性和消费者合理用药期望的治疗药物有着强烈的需求。

从企业层级深入分析了safefur供应链中的竞争定位、研发重点、伙伴关係关係、商业化策略和业务永续营运。

头孢噻呋领域的企业竞争格局取决于其自身能力，包括研发、合规性、生产规模和分销网络。投资于製剂创新（例如浓缩液体製剂和简化农场管理的即用型製剂）的企业，既能满足兽医对便利性和给药准确性的需求，又能实现差异化竞争优势。同样重要的是，企业还需投资于药品监测、品质系统以及与监管机构的合作，以妥善应对不断变化的标籤要求和相关法规，确保正确使用。

为行业领导者提供切实可行的建议，以加强供应链韧性、促进负责任的使用，并透过伙伴关係提高商业性灵活性。

产业领导者应采取一系列切实可行的措施，以平衡疗效、监管责任和供应韧性。首先，企业应投资于关键原料和成品的多供应商合格和双重采购策略，以降低贸易政策变化和物流瓶颈带来的风险。这项营运紧急时应对计画应与基于情境的库存管理政策和合约条款相结合，以便在供应中断时能够迅速重新分配供应。

透明的调查方法，说明了原始资料和二手资料的收集、检验通讯协定、与专家的咨询以及分析安全措施。

本分析采用混合研究方法，结合结构化的原始资料和全面的二手数据，并辅以严格的检验通讯协定。原始数据包括与执业兽医、供应链和监管专家以及行业领袖的专家咨询，这些专家提供了关于临床实践、采购行为和监管合规性的经验观点。二手资料包括公开的监管文件、临床指南和同行评审文献，用于建立临床背景并对原始研究结果进行三角验证。

整合结论，重点强调管理优先事项、持续供应的必要性以及对指导兽药决策者的实际意义。

本文的研究结果总结了与头孢噻呋及相关兽药相关的相关人员应指南的几项核心挑战。管理和监管合规是永续使用的不可或缺的基础。提高诊断准确性和加强处方医师教育的努力将有助于改善临床疗效并提升声誉。强调多元化、合约柔软性和品质保证的供应链策略对于降低贸易政策波动和物流不稳定带来的风险至关重要。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：头孢噻呋市场：路线

  • 注射药物
    • 肌肉内部
    • 静脉
    • 皮下
  • 口服

第九章：头孢噻呋市场：依适应症划分

  • 胃肠道感染疾病
  • 呼吸道感染疾病
    • 牛呼吸道疾病
    • 家禽呼吸道疾病
    • 猪的呼吸系统疾病
  • 全身性行为感染

第十章：头孢噻呋市场以剂型划分

  • 液体
    • 浓缩液
    • 即用型
  • 粉末
  • 预混合料

第十一章：塞夫蒂奥弗鲁市场：以最终用户划分

  • 农场
    • 大型农场
    • 小规模农场
  • 零售药房
  • 动物医院

第十二章：头孢噻呋市场：依动物类型划分

  • 牛
    • 牛
    • 牛
  • 家禽
  • 猪

第十三章：Ceftioful 市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：塞夫蒂欧弗鲁市场：依集团划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：头孢噻呋市场：依国家/地区划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国头孢噻呋市场

第十七章：中国头孢菲芙市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Aurobindo Pharma Limited
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale
  • Chongqing Huapont Pharmaceutical Co., Ltd
  • Cipla Limited
  • Dechra Pharmaceuticals PLC
  • Dr. Reddy's Laboratories Ltd
  • Elanco Animal Health Incorporated
  • Huvepharma EOOD
  • Jiangsu Hengrui Medicine Co., Ltd
  • Lupin Limited
  • Merck & Co., Inc
  • Norbrook Laboratories Ltd
  • Novartis AG
  • Phibro Animal Health Corporation
  • Sanofi SA
  • Shandong Lukang Pharmaceutical Co., Ltd
  • Shanghai Pharmaceuticals Holding Co., Ltd
  • Shenzhen Kangning Pharmaceutical Co., Ltd
  • Sun Pharmaceutical Industries Ltd
  • Vetoquinol SA
  • Virbac SA
  • Zhejiang Hisun Pharmaceutical Co., Ltd
  • Zoetis Inc
Product Code: MRR-1A1A064C0547

The Ceftiofur Market was valued at USD 471.85 million in 2025 and is projected to grow to USD 505.78 million in 2026, with a CAGR of 9.18%, reaching USD 872.82 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 471.85 million
Estimated Year [2026] USD 505.78 million
Forecast Year [2032] USD 872.82 million
CAGR (%) 9.18%

Comprehensive introduction to ceftiofur's therapeutic role in modern veterinary care, regulatory landscape, stewardship expectations, and stakeholder priorities

Ceftiofur remains a cornerstone antimicrobial in veterinary medicine, valued for its broad-spectrum activity and established clinical utility across multiple livestock species. Its role within therapeutic protocols continues to be shaped by evolving clinical evidence, veterinary practice standards, and an intensifying global focus on antimicrobial stewardship. As stakeholders weigh therapeutic benefits against regulatory and public health obligations, a clear understanding of ceftiofur's clinical indications, routes of administration, and formulation options becomes essential for clinicians, farm managers, and supply chain planners alike.

Regulatory frameworks and stewardship expectations vary by jurisdiction, influencing prescribing behavior and product availability. Concurrently, advances in diagnostic capacity and disease surveillance are accelerating the shift from empiric to targeted therapy in many settings, which affects how ceftiofur is used in practice. Economic pressures on producers and distributors, coupled with heightened scrutiny from consumers and regulators, underscore the need for strategic clarity around procurement, inventory management, and responsible use policies. This introduction sets the stage for a focused analysis that integrates clinical, regulatory, and commercial perspectives to support informed decision-making.

Analysis of transformative shifts reshaping ceftiofur application, supply chains, antimicrobial stewardship, and product innovation in veterinary sectors

The landscape in which ceftiofur is developed, distributed, and prescribed is undergoing substantive change driven by regulatory shifts, supply chain reconfiguration, and technological innovation. Heightened regulatory scrutiny and an increasingly stringent stewardship agenda are reshaping product labeling, permissible indications, and dispensing practices. These forces are prompting manufacturers and distributors to reexamine lifecycle strategies, invest in targeted education for prescribers, and explore formulation innovations that support judicious use while maintaining therapeutic efficacy.

At the same time, supply chain pressures-from raw material sourcing to finished-goods logistics-are driving organizations to diversify suppliers, strengthen inventory controls, and adopt more transparent procurement practices. Advancements in diagnostics, including rapid detection tools and improved laboratory networks, are enabling earlier and more accurate disease identification, which in turn informs more precise antimicrobial selection. Collectively, these shifts are encouraging a transition from volume-based distribution models toward value-based approaches that prioritize outcomes, traceability, and long-term sustainability. Stakeholders that anticipate and adapt to these transformative trends will be better positioned to align clinical needs, regulatory expectations, and commercial resilience.

Detailed evaluation of the cumulative economic and operational impact of United States tariffs enacted in 2025 on ceftiofur supply, sourcing, and trade dynamics

The United States tariffs introduced in 2025 have had a multi-dimensional effect on the ceftiofur supply continuum, altering sourcing economics and downstream operational planning. Tariff adjustments increased landed costs for certain active pharmaceutical ingredients and formulated products originating from affected trade partners, prompting procurement teams to reassess supplier portfolios and to accelerate qualification of alternative sources. This response encompassed both near-term tactical shifts-such as re-routing shipments and adjusting safety stock levels-and longer-term strategic decisions to localize or regionalize critical sourcing.

Pricing pressures were complemented by logistical constraints as some suppliers prioritized markets with fewer trade frictions, thereby creating short windows of constrained availability for distributors and end users. Regulatory compliance and quality-assurance requirements limited the universe of acceptable alternative sources, which added complexity to supplier transitions. In response, many organizations enhanced contract flexibility and invested in scenario planning to maintain supply continuity. The tariff-induced environment also catalyzed conversations about vertical integration and contractual hedging to reduce exposure to future trade policy volatility. As a result, stakeholders are increasingly embedding geopolitical risk assessments into procurement planning and clinical continuity strategies.

In-depth segmentation insights on how animal type, clinical indications, administration routes, formulation choices and end-user profiles shape use patterns

Segmentation analysis illuminates how therapeutic use and commercial priorities diverge across animal types, clinical indications, routes of administration, formulation preferences, and end-user settings. Within animal type, the market is differentiated by Cattle, Poultry, and Swine, with Cattle further subdivided into Beef Cattle and Dairy Cattle; each segment exhibits distinct disease profiles, dosing regimens, and economic tolerances that influence product selection and administration strategies. Disease indication segmentation shows varied use across Gastrointestinal Infections, Respiratory Infections, and Systemic Infections, and the respiratory category is further distinguished by Bovine Respiratory Disease, Poultry Respiratory Disease, and Swine Respiratory Disease, reflecting species-specific pathogen prevalence and management practices.

Route-based segmentation highlights the predominance of Injectable and Oral administration, with the Injectable route further differentiated into Intramuscular, Intravenous, and Subcutaneous approaches that carry implications for dosing accuracy, withdrawal periods, and on-farm administration logistics. Formulation analysis distinguishes Liquid, Powder, and Premix offerings, where Liquid products are further categorized into Concentrate and Ready To Use variants that affect handling, storage, and dosing convenience. End-user segmentation underscores divergent procurement behaviors and usage patterns across Farm, Retail Pharmacies, and Veterinary Clinics, with Farm users split into Large Farms and Small Farms; these distinctions drive preferences for pack sizes, formulation types, and service-level expectations. Together, these segmentation lenses enable a granular understanding of demand drivers and operational constraints, and inform targeted strategies for product development, distribution, and stewardship initiatives.

Regional intelligence that synthesizes drivers, regulatory environments, supply chain realities, and clinical demand trends across major global regions

Regional dynamics play a decisive role in how ceftiofur is regulated, accessed, and deployed, with distinct patterns emerging across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, regulatory harmonization efforts coexist with significant heterogeneity at the national level, influencing licensing timelines and prescribing norms. The region's large commercial livestock sectors emphasize productivity and disease prevention, which results in strong demand for therapeutics that balance efficacy with regulatory compliance and consumer expectations for responsible use.

Europe, Middle East & Africa present a varied regulatory tapestry where stewardship imperatives and consumer-facing transparency demands are especially pronounced in many European markets, while certain EMEA territories are still building diagnostic and distribution infrastructures. Asia-Pacific demonstrates fast-evolving demand patterns driven by rapid intensification of production systems, expanding veterinary services, and increasing regulatory attention to antimicrobial resistance. Across all regions, supply chain resilience, regulatory clarity, and the availability of veterinary expertise are the primary determinants of how ceftiofur is positioned and utilized. Businesses that tailor commercial approaches to regional regulatory climates, distribution realities, and clinical priorities will find better alignment with local stakeholders and greater operational success.

Strategic company-level insights spotlighting competitive positioning, R&D focus, partnerships, commercialization tactics and operational resilience in ceftiofur supply

Competitive dynamics among companies operating in the ceftiofur space are defined by capabilities in R&D, regulatory affairs, manufacturing scale, and distribution reach. Firms that invest in formulation innovation, such as concentrated liquid formats or ready-to-use presentations that simplify on-farm administration, can secure differentiation while addressing practitioner preference for convenience and dosing accuracy. Equally important are investments in pharmacovigilance, quality systems, and regulatory engagement to navigate evolving labeling requirements and stewardship-related restrictions.

Strategic partnerships and contract manufacturing relationships have become critical levers for operational continuity, enabling flexibility in sourcing and capacity scaling. Companies with diversified supply chains and transparent traceability practices have demonstrated greater resilience to trade disruptions and regulatory shifts. Commercially, successful organizations often combine evidence-based education for veterinarians and farm personnel with targeted support services that address withdrawal management, dosing optimization, and stewardship compliance. Those that align their R&D and commercialization strategies with prevailing clinical needs and regulatory expectations are better positioned to retain trust among prescribers and end users while maintaining operational stability.

Actionable recommendations for industry leaders to strengthen supply chain resilience, promote responsible use, and enhance commercial agility through partnerships

Industry leaders should adopt a pragmatic set of actions to balance therapeutic effectiveness with regulatory responsibility and supply resilience. First, firms should invest in multi-source qualification and dual-sourcing strategies for critical inputs and finished products to reduce vulnerability to trade policy changes and logistical bottlenecks. This operational contingency planning should be paired with scenario-based inventory policies and contractual terms that permit rapid reallocation of supply when disruptions occur.

Second, strengthening stewardship requires coordinated investment in diagnostics, practitioner education, and data capture to enable targeted therapy and to demonstrate responsible use. Third, formulation and route optimization-including exploration of ready-to-use liquid presentations and administration protocols that lower the risk of dosing errors-can improve adherence and reduce inadvertent selection pressure. Fourth, commercial strategies should prioritize transparent engagement with regulators, veterinarians, and farm operators to align on labeling, withdrawal guidance, and usage monitoring. Finally, leaders should pursue partnerships that enhance distribution agility and invest in analytics that convert operational data into actionable intelligence for procurement, pharmacovigilance, and clinical outcomes tracking. Together these actions create a pragmatic roadmap for operational and clinical resilience.

Transparent research methodology describing primary and secondary data collection, validation protocols, expert consultation, and analytic safeguards

This analysis is grounded in a mixed-methods research approach that combines structured primary research with comprehensive secondary review and rigorous validation protocols. Primary inputs include expert consultations with practicing veterinarians, supply chain and regulatory specialists, and commercial leaders, all of whom provide grounded perspectives on clinical practice, procurement behavior, and regulatory compliance. Secondary inputs consist of publicly available regulatory documents, clinical guidelines, and peer-reviewed literature used to establish clinical context and to triangulate primary findings.

Data validation was achieved through cross-verification of supplier and regulatory information across multiple sources, and by reconciling practitioner-reported behaviors with documented industry trends. Analytical methods included thematic synthesis for qualitative inputs and scenario analysis for supply chain and policy-driven impacts. Limitations are acknowledged, including variability in regional data transparency and the evolving nature of regulatory guidance; where appropriate, assumptions are explicitly stated and sensitivity considerations are applied. The methodology emphasizes transparency and reproducibility to ensure that conclusions are robust and relevant for decision-makers.

Concluding synthesis highlighting stewardship priorities, supply continuity imperatives, and practical implications to guide decision-makers in veterinary therapeutics

The cumulative insights presented here converge on several core imperatives that should guide stakeholders engaged with ceftiofur and related veterinary therapeutics. Stewardship and regulatory alignment are non-negotiable foundations for sustainable use; efforts to improve diagnostic precision and to educate prescribers will yield dividends in both clinical outcomes and reputational resilience. Supply chain strategies that emphasize diversification, contractual flexibility, and quality assurance are essential to mitigate exposure to trade policy shifts and logistical volatility.

Commercial success will increasingly depend on the ability to tailor product offerings and service models to differentiated end-user needs, whether those are large integrated farms seeking scalable solutions or smaller operations that require more hands-on support. Companies that invest in responsible-use messaging, transparent traceability, and collaborative partnerships with veterinary stakeholders will be best placed to navigate evolving regulatory landscapes and to sustain clinical relevance. The synthesis underscores the importance of integrating clinical, operational, and commercial perspectives to drive pragmatic, evidence-based decisions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Ceftiofur Market, by Route

  • 8.1. Injectable
    • 8.1.1. Intramuscular
    • 8.1.2. Intravenous
    • 8.1.3. Subcutaneous
  • 8.2. Oral

9. Ceftiofur Market, by Indication

  • 9.1. Gastrointestinal Infections
  • 9.2. Respiratory Infections
    • 9.2.1. Bovine Respiratory Disease
    • 9.2.2. Poultry Respiratory Disease
    • 9.2.3. Swine Respiratory Disease
  • 9.3. Systemic Infections

10. Ceftiofur Market, by Formulation

  • 10.1. Liquid
    • 10.1.1. Concentrate
    • 10.1.2. Ready To Use
  • 10.2. Powder
  • 10.3. Premix

11. Ceftiofur Market, by End User

  • 11.1. Farm
    • 11.1.1. Large Farms
    • 11.1.2. Small Farms
  • 11.2. Retail Pharmacies
  • 11.3. Veterinary Clinics

12. Ceftiofur Market, by Animal Type

  • 12.1. Cattle
    • 12.1.1. Beef Cattle
    • 12.1.2. Dairy Cattle
  • 12.2. Poultry
  • 12.3. Swine

13. Ceftiofur Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Ceftiofur Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Ceftiofur Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Ceftiofur Market

17. China Ceftiofur Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Aurobindo Pharma Limited
  • 18.6. Bayer AG
  • 18.7. Boehringer Ingelheim International GmbH
  • 18.8. Ceva Sante Animale
  • 18.9. Chongqing Huapont Pharmaceutical Co., Ltd
  • 18.10. Cipla Limited
  • 18.11. Dechra Pharmaceuticals PLC
  • 18.12. Dr. Reddy's Laboratories Ltd
  • 18.13. Elanco Animal Health Incorporated
  • 18.14. Huvepharma EOOD
  • 18.15. Jiangsu Hengrui Medicine Co., Ltd
  • 18.16. Lupin Limited
  • 18.17. Merck & Co., Inc
  • 18.18. Norbrook Laboratories Ltd
  • 18.19. Novartis AG
  • 18.20. Phibro Animal Health Corporation
  • 18.21. Sanofi S.A.
  • 18.22. Shandong Lukang Pharmaceutical Co., Ltd
  • 18.23. Shanghai Pharmaceuticals Holding Co., Ltd
  • 18.24. Shenzhen Kangning Pharmaceutical Co., Ltd
  • 18.25. Sun Pharmaceutical Industries Ltd
  • 18.26. Vetoquinol SA
  • 18.27. Virbac S.A.
  • 18.28. Zhejiang Hisun Pharmaceutical Co., Ltd
  • 18.29. Zoetis Inc

LIST OF FIGURES

  • FIGURE 1. GLOBAL CEFTIOFUR MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CEFTIOFUR MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CEFTIOFUR MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CEFTIOFUR MARKET SIZE, BY ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CEFTIOFUR MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CEFTIOFUR MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CEFTIOFUR MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CEFTIOFUR MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CEFTIOFUR MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CEFTIOFUR MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CEFTIOFUR MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CEFTIOFUR MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CEFTIOFUR MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CEFTIOFUR MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CEFTIOFUR MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CEFTIOFUR MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CEFTIOFUR MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CEFTIOFUR MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CEFTIOFUR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CEFTIOFUR MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CEFTIOFUR MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CEFTIOFUR MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CEFTIOFUR MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CEFTIOFUR MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CEFTIOFUR MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CEFTIOFUR MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CEFTIOFUR MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CEFTIOFUR MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CEFTIOFUR MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CEFTIOFUR MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CEFTIOFUR MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CEFTIOFUR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CEFTIOFUR MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CEFTIOFUR MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CEFTIOFUR MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CEFTIOFUR MARKET SIZE, BY RESPIRATORY INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CEFTIOFUR MARKET SIZE, BY RESPIRATORY INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CEFTIOFUR MARKET SIZE, BY RESPIRATORY INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CEFTIOFUR MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CEFTIOFUR MARKET SIZE, BY BOVINE RESPIRATORY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CEFTIOFUR MARKET SIZE, BY BOVINE RESPIRATORY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CEFTIOFUR MARKET SIZE, BY BOVINE RESPIRATORY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CEFTIOFUR MARKET SIZE, BY POULTRY RESPIRATORY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CEFTIOFUR MARKET SIZE, BY POULTRY RESPIRATORY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CEFTIOFUR MARKET SIZE, BY POULTRY RESPIRATORY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CEFTIOFUR MARKET SIZE, BY SWINE RESPIRATORY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CEFTIOFUR MARKET SIZE, BY SWINE RESPIRATORY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CEFTIOFUR MARKET SIZE, BY SWINE RESPIRATORY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CEFTIOFUR MARKET SIZE, BY SYSTEMIC INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CEFTIOFUR MARKET SIZE, BY SYSTEMIC INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CEFTIOFUR MARKET SIZE, BY SYSTEMIC INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CEFTIOFUR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CEFTIOFUR MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CEFTIOFUR MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CEFTIOFUR MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CEFTIOFUR MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CEFTIOFUR MARKET SIZE, BY CONCENTRATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CEFTIOFUR MARKET SIZE, BY CONCENTRATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CEFTIOFUR MARKET SIZE, BY CONCENTRATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CEFTIOFUR MARKET SIZE, BY READY TO USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CEFTIOFUR MARKET SIZE, BY READY TO USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CEFTIOFUR MARKET SIZE, BY READY TO USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CEFTIOFUR MARKET SIZE, BY POWDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CEFTIOFUR MARKET SIZE, BY POWDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CEFTIOFUR MARKET SIZE, BY POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CEFTIOFUR MARKET SIZE, BY PREMIX, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CEFTIOFUR MARKET SIZE, BY PREMIX, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CEFTIOFUR MARKET SIZE, BY PREMIX, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CEFTIOFUR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CEFTIOFUR MARKET SIZE, BY FARM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CEFTIOFUR MARKET SIZE, BY FARM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CEFTIOFUR MARKET SIZE, BY FARM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CEFTIOFUR MARKET SIZE, BY FARM, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CEFTIOFUR MARKET SIZE, BY LARGE FARMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CEFTIOFUR MARKET SIZE, BY LARGE FARMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CEFTIOFUR MARKET SIZE, BY LARGE FARMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CEFTIOFUR MARKET SIZE, BY SMALL FARMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CEFTIOFUR MARKET SIZE, BY SMALL FARMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CEFTIOFUR MARKET SIZE, BY SMALL FARMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CEFTIOFUR MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CEFTIOFUR MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CEFTIOFUR MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CEFTIOFUR MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CEFTIOFUR MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CEFTIOFUR MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CEFTIOFUR MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CEFTIOFUR MARKET SIZE, BY CATTLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CEFTIOFUR MARKET SIZE, BY CATTLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CEFTIOFUR MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CEFTIOFUR MARKET SIZE, BY CATTLE, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CEFTIOFUR MARKET SIZE, BY BEEF CATTLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CEFTIOFUR MARKET SIZE, BY BEEF CATTLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CEFTIOFUR MARKET SIZE, BY BEEF CATTLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CEFTIOFUR MARKET SIZE, BY DAIRY CATTLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CEFTIOFUR MARKET SIZE, BY DAIRY CATTLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CEFTIOFUR MARKET SIZE, BY DAIRY CATTLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CEFTIOFUR MARKET SIZE, BY POULTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CEFTIOFUR MARKET SIZE, BY POULTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CEFTIOFUR MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CEFTIOFUR MARKET SIZE, BY SWINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CEFTIOFUR MARKET SIZE, BY SWINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CEFTIOFUR MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CEFTIOFUR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS CEFTIOFUR MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS CEFTIOFUR MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS CEFTIOFUR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS CEFTIOFUR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS CEFTIOFUR MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS CEFTIOFUR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS CEFTIOFUR MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS CEFTIOFUR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS CEFTIOFUR MARKET SIZE, BY FARM, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS CEFTIOFUR MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS CEFTIOFUR MARKET SIZE, BY CATTLE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA CEFTIOFUR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA CEFTIOFUR MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA CEFTIOFUR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA CEFTIOFUR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA CEFTIOFUR MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA CEFTIOFUR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA CEFTIOFUR MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA CEFTIOFUR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA CEFTIOFUR MARKET SIZE, BY FARM, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA CEFTIOFUR MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA CEFTIOFUR MARKET SIZE, BY CATTLE, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA CEFTIOFUR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA CEFTIOFUR MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA CEFTIOFUR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA CEFTIOFUR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA CEFTIOFUR MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA CEFTIOFUR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA CEFTIOFUR MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA CEFTIOFUR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA CEFTIOFUR MARKET SIZE, BY FARM, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA CEFTIOFUR MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA CEFTIOFUR MARKET SIZE, BY CATTLE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA CEFTIOFUR MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA CEFTIOFUR MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA CEFTIOFUR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA CEFTIOFUR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA CEFTIOFUR MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA CEFTIOFUR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA CEFTIOFUR MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA CEFTIOFUR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA CEFTIOFUR MARKET SIZE, BY FARM, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA CEFTIOFUR MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA CEFTIOFUR MARKET SIZE, BY CATTLE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE CEFTIOFUR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE CEFTIOFUR MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE CEFTIOFUR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE CEFTIOFUR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE CEFTIOFUR MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE CEFTIOFUR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE CEFTIOFUR MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE CEFTIOFUR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE CEFTIOFUR MARKET SIZE, BY FARM, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE CEFTIOFUR MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE CEFTIOFUR MARKET SIZE, BY CATTLE, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST CEFTIOFUR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST CEFTIOFUR MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST CEFTIOFUR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST CEFTIOFUR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST CEFTIOFUR MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST CEFTIOFUR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST CEFTIOFUR MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST CEFTIOFUR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST CEFTIOFUR MARKET SIZE, BY FARM, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST CEFTIOFUR MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST CEFTIOFUR MARKET SIZE, BY CATTLE, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA CEFTIOFUR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA CEFTIOFUR MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA CEFTIOFUR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA CEFTIOFUR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA CEFTIOFUR MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA CEFTIOFUR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA CEFTIOFUR MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA CEFTIOFUR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA CEFTIOFUR MARKET SIZE, BY FARM, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA CEFTIOFUR MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA CEFTIOFUR MARKET SIZE, BY CATTLE, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC CEFTIOFUR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC CEFTIOFUR MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC CEFTIOFUR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC CEFTIOFUR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC CEFTIOFUR MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC CEFTIOFUR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC CEFTIOFUR MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC CEFTIOFUR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC CEFTIOFUR MARKET SIZE, BY FARM, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC CEFTIOFUR MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC CEFTIOFUR MARKET SIZE, BY CATTLE, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL CEFTIOFUR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN CEFTIOFUR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN CEFTIOFUR MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN CEFTIOFUR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN CEFTIOFUR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN CEFTIOFUR MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN CEFTIOFUR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN CEFTIOFUR MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN CEFTIOFUR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN CEFTIOFUR MARKET SIZE, BY FARM, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN CEFTIOFUR MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN CEFTIOFUR MARKET SIZE, BY CATTLE, 2018-2032 (USD MILLION)
  • TABLE 191. GCC CEFTIOFUR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. GCC CEFTIOFUR MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 193. GCC CEFTIOFUR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 194. GCC CEFTIOFUR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 195. GCC CEFTIOFUR MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 196. GCC CEFTIOFUR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 197. GCC CEFTIOFUR MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 198. GCC CEFTIOFUR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. GCC CEFTIOFUR MARKET SIZE, BY FARM, 2018-2032 (USD MILLION)
  • TABLE 200. GCC CEFTIOFUR MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. GCC CEFTIOFUR MARKET SIZE, BY CATTLE, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION CEFTIOFUR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION CEFTIOFUR MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION CEFTIOFUR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION CEFTIOFUR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION CEFTIOFUR MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION CEFTIOFUR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION CEFTIOFUR MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION CEFTIOFUR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION CEFTIOFUR MARKET SIZE, BY FARM, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION CEFTIOFUR MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION CEFTIOFUR MARKET SIZE, BY CATTLE, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS CEFTIOFUR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS CEFTIOFUR MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS CEFTIOFUR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS CEFTIOFUR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS CEFTIOFUR MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS CEFTIOFUR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS CEFTIOFUR MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS CEFTIOFUR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS CEFTIOFUR MARKET SIZE, BY FARM, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS CEFTIOFUR MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS CEFTIOFUR MARKET SIZE, BY CATTLE, 2018-2032 (USD MILLION)
  • TABLE 224. G7 CEFTIOFUR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. G7 CEFTIOFUR MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 226. G7 CEFTIOFUR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 227. G7 CEFTIOFUR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 228. G7 CEFTIOFUR MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 229. G7 CEFTIOFUR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 230. G7 CEFTIOFUR MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 231. G7 CEFTIOFUR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. G7 CEFTIOFUR MARKET SIZE, BY FARM, 2018-2032 (USD MILLION)
  • TABLE 233. G7 CEFTIOFUR MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. G7 CEFTIOFUR MARKET SIZE, BY CATTLE, 2018-2032 (USD MILLION)
  • TABLE 235. NATO CEFTIOFUR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 236. NATO CEFTIOFUR MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 237. NATO CEFTIOFUR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 238. NATO CEFTIOFUR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 239. NATO CEFTIOFUR MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 240. NATO CEFTIOFUR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 241. NATO CEFTIOFUR MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 242. NATO CEFTIOFUR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. NATO CEFTIOFUR MARKET SIZE, BY FARM, 2018-2032 (USD MILLION)
  • TABLE 244. NATO CEFTIOFUR MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. NATO CEFTIOFUR MARKET SIZE, BY CATTLE, 2018-2032 (USD MILLION)
  • TABLE 246. GLOBAL CEFTIOFUR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES CEFTIOFUR MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES CEFTIOFUR MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES CEFTIOFUR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES CEFTIOFUR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES CEFTIOFUR MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES CEFTIOFUR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES CEFTIOFUR MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES CEFTIOFUR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES CEFTIOFUR MARKET SIZE, BY FARM, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES CEFTIOFUR MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES CEFTIOFUR MARKET SIZE, BY CATTLE, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA CEFTIOFUR MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA CEFTIOFUR MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA CEFTIOFUR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA CEFTIOFUR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA CEFTIOFUR MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA CEFTIOFUR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA CEFTIOFUR MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA CEFTIOFUR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA CEFTIOFUR MARKET SIZE, BY FARM, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA CEFTIOFUR MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA CEFTIOFUR MARKET SIZE, BY CATTLE, 2018-2032 (USD MILLION)